Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases

Park, Ji Yoon; Park, Jun Hyoung; Jang, Woo Hyuk; Hwang, In Kwan; Kim, In Ja; Kim, Hwa Jung; Cho, Kyung Hyun; Lee, Seung Taek

doi:10.1093/jb/mvr137

Cited by 24 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wang et al reported that apoA-IV improves glucose homeostasis by enhancing insulin secretion [22]. A recent report suggested that apoA-IV seems to play a protective role against atherosclerosis by virtue of both its classical roles in lipid metabolism and its antioxidant properties [23]. Also, rodent studies have demonstrated the protective role of apoA-IV in the development and progression of atherosclerosis [18,24], and a previous study suggested that hypercholesterolemia is a risk factor for CTS [25].…”

Section: Discussionmentioning

confidence: 99%

Proteomic Evaluation to Identify Biomarkers for Carpal Tunnel Syndrome: A Comparative Serum Analysis

Kwak

et al. 2012

Connective Tissue Research

View full text Add to dashboard Cite

Carpal tunnel syndrome (CTS) is the most common peripheral nerve entrapment, causing pain, impairment, and disability. To identify proteins of CTS comprehensively, a comparative serum analysis of CTS patients and normal control subjects was performed. The two-dimensional electrophoresis patterns of serum obtained from six CTS patients and six normal control subjects were compared. We found 10 proteins that were significantly altered in the serum of CTS patients, among which four were upregulated and six were downregulated. The upregulated spots were identified as Chain A, heat shock 70-kDa protein, 42-kDa ATPase N-terminal domain; glutathione-insulin transhydrogenase (216AA); cAMP-dependent protein kinase inhibitor alpha; and mutant β-globin. The downregulated spots were identified as vitamin D-binding protein (VDBP), fibrinogen gamma chain, apolipoprotein A-IV (ApoA-IV), clusterin, heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1), and one unidentified protein. The information obtained from this proteomic analysis will be very useful in understanding the pathophysiology of CTS and in finding suitable proteins that can serve as new diagnostic biomarkers of CTS.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomic Evaluation to Identify Biomarkers for Carpal Tunnel Syndrome: A Comparative Serum Analysis

Kwak

et al. 2012

Connective Tissue Research

View full text Add to dashboard Cite

show abstract

“…Apolipoproteins are also activators of lipoprotein lipase and of lecithin-cholesterol acyl transferase, which release fatty acids and cholesterol, respectively, from lipoparticles such as chylomicrons and VLDLs [191]. Apolipoprotein C-II, apolipoprotein A-I, apolipoprotein A-IV, and apolipoprotein E can all be cleaved by MMP-7 and MT1-MMP [192,193,194,195,196]. By cleaving apolipoproteins, the activation of either MMP-7 or MT1-MMP during hypertensive cardiac disease could reduce the clearance of lipoparticles from circulation and impair the release of lipids from lipoparticles.…”

Section: Lipoprotein Regulation By Mmpsmentioning

confidence: 99%

Insights into the Activity, Differential Expression, Mutual Regulation, and Functions of Matrix Metalloproteinases and A Disintegrin and Metalloproteinases in Hypertension and Cardiac Disease

Berry

Bosonea²,

Wang³

et al. 2012

J Vasc Res

View full text Add to dashboard Cite

Hypertensive cardiac disease is a major cause of death worldwide. Causative factors of hypertension include environmental stressors, genetic predisposition, and common morbidities of lipid metabolism such as obesity and diabetes. These factors pathologically elevate the systemic production of vasoconstrictive G-protein-coupled receptor agonists. Pathological concentrations of these agonists upregulate the gene expression and proteolytic activity of matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinases (ADAMs). Among the metalloproteinases that act in concert with other mediators to elevate the systemic blood pressure and to modulate the development of cardiovascular hypertrophy and fibrosis processes are MMP-2, MMP-7, ADAM-12, and ADAM-17. This review offers insights into the activity, differential expression, mutual regulation, and functions of these metalloproteinases. We further review evidence linking them to transcription factors, carrier proteins, and receptors for lipids. The emerging links between metalloproteinases and lipids are intriguing and suggest new therapeutic targets in hypertensive cardiac disease.

show abstract

“…More recently a study suggested that Apo A-IV in plasma can be cleaved by matrix metalloproteinase (MMP)-7 into several fragments of 41, 32, 29, 27, 24, 22 and 19 kDa. The MMP-7-mediated cleavage of apo A-IV resulted in a rapid loss of its intrinsic anti-oxidant activity [44]. In the present study, we report that fragmented Apo A-IV (∼26 kDa) was almost removed in serum from PD patients for the first time, meanwhile, the levels of full size Apo A-IV (46 kDa) was not changed in PD serum validated by western blot, suggesting that the disregulation of the protein may play a role in the pathogenesis of PD.…”

Section: Discussionmentioning

confidence: 99%

Specific Changes of Serum Proteins in Parkinson's Disease Patients

Wan

Liu

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

The aim of this study is to identify and validate protein change in the serum from PD patients. We used serum samples from 21 PD patients and 20 age-matched normal people as control to conduct a comparative proteomic study. We performed 2-DE and analyzed the differentially expressed protein spots by LC-MS/MS. In PD group 13 spots were shown to be differentially expressed compared to control group. They were identified as 6 proteins. Among these, 3 proteins were confirmed by Western blot analysis. It showed that the frequency of fibrinogen γ-chain (FGG) appeared 70% in PD, which could not be detected in control group. The protein of inter-alpha-trypsin inhibitor heavy chain H4 (ITI-H4) was found to exist two forms in serum. The full size (120 kDa) of the protein was increased and the fragmented ITI-H4 (35 kDa) was decreased in PD group. The ratio of full size ITI-H4 to fragmented ITI-H4 in PD patients was 3.85±0.29-fold higher than in control group. Furthermore, fragmented Apo A-IV (∼26 kDa) was mainly detected in control group, while it was rare to be found in PD group. Above findings might be useful for diagnosis of PD. When the expressions of FGG and 120 kDa ITI-H4 are increase, as well as ∼26 kDa Apo A-IV disappear would provide strong evidence for PD.

show abstract

Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases

Cited by 24 publications

References 37 publications

Proteomic Evaluation to Identify Biomarkers for Carpal Tunnel Syndrome: A Comparative Serum Analysis

Proteomic Evaluation to Identify Biomarkers for Carpal Tunnel Syndrome: A Comparative Serum Analysis

Insights into the Activity, Differential Expression, Mutual Regulation, and Functions of Matrix Metalloproteinases and A Disintegrin and Metalloproteinases in Hypertension and Cardiac Disease

Specific Changes of Serum Proteins in Parkinson's Disease Patients

Contact Info

Product

Resources

About